|
|
Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus’ lead drug candidate, APL-130277, is a reformulation of an approved drug for the treatment of motor fluctuation in Parkinson’s disease. APL-130277 is designed to be a convenient, fast-acting rescue of patients experiencing motor fluctuations from “off” episodes during the day. The reformulation could address a much larger moderate to severe patient population, which represents approximately 25% to 50% of Parkinson’s patients.
|
